Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
Syndax reported Q1 2026 total revenue of $64.9 million, a 224% year-over-year increase, driven by strong sales of its two commercial-stage medicines. Revuforj net revenue reached $48.9 million, up 144% from the prior year, while Niktimvo contributed $15.9 million in collaboration revenue based on $55.1 million in total product sales.
Key figures
- Revenue
- 64900000
- Guidance
- FY2026 total R&D plus SG&A expenses expected to be ~$400M
- Revenue Yoy
- 224%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.